Financial Performance - Total revenues increased by $0.8 million or 2.0% from $42.6 million in 2018 to $43.4 million in 2019, primarily due to a 10.6% increase in G6 product sales[200] - Gross profit rose by $0.5 million or 2.7% from $17.5 million in 2018 to $17.9 million in 2019, with gross margin improving from 41.0% to 41.3%[202] - Net loss narrowed to $8.8 million in 2019 from $12.8 million in 2018, with a loss from operations improving from (30.2%) to (20.7%) of revenues[192][199] Expenses - Research and development expenses decreased by $0.3 million or 8.1% from $4.0 million in 2018 to $3.7 million in 2019[204] - Sales and marketing expenses fell by $1.9 million or 11.5%, from $16.8 million in 2018 to $14.9 million in 2019[205] - General and administrative expenses decreased by $1.2 million or 12.3% from $9.6 million in 2018 to $8.4 million in 2019[206] Cash Flow and Liquidity - Cash and cash equivalents decreased to $12.7 million as of December 28, 2019, down from $21.2 million at the end of 2018[210] - Net cash used in operating activities improved to $7.9 million in 2019 from $10.0 million in 2018, driven by higher cash collections and reduced operating expenses[211] - The company believes existing cash and cash equivalents and available credit will be sufficient to meet anticipated cash needs over the next 12 months[214] Tax and Valuation - The company recorded a provision for income taxes of $48 thousand in 2019, compared to $37 thousand in 2018, with an effective tax rate of negative 0.46%[208] - As of December 28, 2019, a full valuation allowance was provided on federal and state deferred tax assets due to recent history of losses[224] Inventory and Reserves - Inventories are stated at the lower of cost or net realizable value, with adjustments made for estimated excess, obsolete, or impaired inventory[220] - The company maintains allowances for doubtful accounts based on past payment history, current financial condition, and aging of accounts receivable[222] - Warranty reserves are provided based on historical product failure rates and expected costs, with a general two-year warranty on products[223] Accounting Standards and Disclosures - The company adopted ASU 2016-02 on December 30, 2018, resulting in an increase in assets of $4.0 million and liabilities of $4.5 million due to operating lease obligations[231] - The company early adopted ASU 2018-13 in fiscal year 2019, which did not have a material impact on consolidated financial statements[232] - The company does not have any off-balance sheet arrangements[235] - As a smaller reporting company, the company is not required to provide certain market risk disclosures[236]

IRIDEX Corp (NASDAQ:IRIX) Q4 2019 Earnings Conference Call March 12, 2020 5:00 PM ET Company Participants Leigh Salvo - Head, IR David Bruce - President, CEO & Director Romeo Dizon - VP, Finance & Controller Conference Call Participants Jonathan Block - Stifel, Nicolaus & Company Scott Henry - Roth Capital Partners Operator Ladies and gentlemen, thank you for standing by, and welcome to the IRIDEX Fourth Quarter 2019 Earnings Call. [Operator Instructions]. I would now like to hand the conference over to you ...

Glaucoma Market and Solution - The global glaucoma market is a $5 billion market [7] - IRIDEX offers MicroPulse Transscleral Laser Therapy as a non-incisional solution for glaucoma, targeting ciliary body tissue to reduce IOP [11] - Clinical outcomes show a 39% IOP reduction at a mean of 78 months follow-up [8, 14] - Over 120,000 MicroPulse procedures have been performed globally since 2015 [16] Market Opportunity and Penetration - The U S probe opportunity is estimated at $500 million [12] - The Rest of World (ROW) probe opportunity is estimated at $700 million [13] - IRIDEX's U S 2019 MP3 probe run rate is 25,000 [12] - IRIDEX's ROW 2019 MP3 volume run rate is 25,000 [13] Financials and Growth - 2019 Revenue Guidance is $41 million to $44 million [27] - As of September 28, 2019, IRIDEX had $12 9 million in cash and no debt [27]

IRIDEX Corporation (NASDAQ:IRIX) Q3 2019 Earnings Conference Call November 7, 2019 5:00 PM ET Company Participants Leigh Salvo – Head of Investors Relations Dave Bruce – Chief Executive Officer Romeo Dizon – Vice President of Finance Conference Call Participants Scott Henry – Roth Capital Operator Ladies and gentlemen, thank you for standing by, and welcome to the Q3 2019 IRIDEX Earnings Conference Call. [Operator Instructions] Please be advised that todayÂ's conference is being recorded. [Operator Instruct ...

IRIDEX Corp (NASDAQ:IRIX) Q2 2019 Earnings Conference Call August 6, 2019 5:00 PM ET Company Participants Leigh Salvo - Head, Investor Relations David Bruce - President and Chief Executive Officer Romeo Dizon - Vice President of Finance Conference Call Participants Trevor Brown - Stifel, Nicolaus & Company Scott Henry - Roth Capital Operator Good day, ladies and gentlemen, and welcome to the IRIDEX Q2 2019 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call may be recorded. ...

Financial Data and Key Metrics Changes - Total revenues for Q1 2019 were $10.6 million, an increase of 11% compared to Q1 2018 [26] - Gross margin in Q1 2019 was 40.2%, down from 41.2% in Q1 2018 [31] - Operating loss in Q1 2019 was $3.0 million, improved from a loss of $3.6 million in the same period last year [31] - Cash and cash equivalents stood at $17.2 million, with no debt and working capital of $25.4 million [32] Business Line Data and Key Metrics Changes - Cyclo G6 product revenue grew by approximately 9% year-over-year to $3.1 million, representing 29% of total revenue [10][27] - Retina product revenues were $5.6 million, an increase of approximately 14% year-over-year, accounting for 53% of total revenue [23][29] - Cyclo G6 systems shipped totaled 114 units, with probe shipments reaching approximately 14,000, a quarterly record [11][28] Market Data and Key Metrics Changes - Approximately 53% of Cyclo G6 revenue was generated in the U.S., while 47% was from outside the U.S. [29] - In the retina business, approximately 47% of revenue was from the U.S. and 53% from outside the U.S. [30] - Strong performance noted in Japan and South Korea, driven by positive KOL influence [16] Company Strategy and Development Direction - The company aims to expand its clinical field team to support sales and increase awareness of MicroPulse technology [8] - Plans to launch the new MicroPulse P3 probe and a new laser platform are underway, expected to improve cost-effectiveness and operational efficiency [24][25] - The focus is on increasing utilization rates among existing customers and expanding the customer base [13][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow neutrality within the next 4 to 5 quarters, supported by growth in top-line revenue and cost containment measures [32] - The company anticipates Cyclo G6 probe shipments of 58,000 to 63,000 for 2019, representing a growth of approximately 32% year-over-year at the midpoint [33] - Management highlighted the importance of maintaining high visibility in the industry and driving brand awareness through participation in key conferences [21][22] Other Important Information - The company had a strong presence at major glaucoma conferences, with over 40 scientific presentations scheduled for the year [19][20] - Regulatory clearance for the Cyclo G6 system in China is in the final review stage, with product registration expected soon [18] Q&A Session Summary Question: Can you break down the installed base of G6 lasers in terms of utilization? - Management indicated that approximately 290 accounts are underperforming, and clinical specialists are focused on improving their utilization rates [36][37] Question: What is the commercialization strategy for China if approved? - Management stated that they have a partner with extensive infrastructure in China, and they anticipate a quick turnaround for commercialization once approval is received [40][41] Question: Why were gross margins lower than expected? - Management explained that lower margins were due to a higher percentage of OUS sales, which typically have lower margins [43] Question: Should pricing improve in the second half of the year? - Management confirmed that pricing is expected to improve significantly in the second half of the year due to the LAP program affecting revenue recognition [46][47] Question: What is the outlook for expenses going forward? - Management indicated that expenses are expected to remain lower due to cost containment measures, while still investing in growth [50][51]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITY EXCHANGE ACT OF 1934 For the fiscal year ended December 29, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITY EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-27598 IRIDEX CORPORATION (Exact name of Registrant as specified in its charter) Delaware 77-0210467 (State or other jurisdiction of incorpora ...

IRIDEX Corporation (NASDAQ:IRIX) Q4 2018 Earnings Conference Call March 5, 2019 5:00 PM ET Company Participants Leigh Salvo - Head of Investor Relations Will Moore - President and Chief Executive Officer Romeo Dizon - Vice President and Controller Conference Call Participants John Block - Stifel Scott Henry - ROTH Capital Operator Good afternoon, ladies and gentlemen, and welcome to today's conference call to discuss IRIDEX Fourth Quarter and Full Year 2018's Financial Results. My name is Soni [ph] and I'll ...